SOST and Dravet syndrome: Sclerostin antibody treatment significantly stimulated bone mass in wild‐type mice and normalized bone mass in Ts65Dn DS mice, via a mechanism that was osteoblast‐mediated with little or no impact on osteoclastogenesis.